Ankylosing Spondylitis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug, By End Use, By Region & Competition, 2020-2030F

Description

Global Ankylosing Spondylitis (AS) therapeutics market was valued at USD 5.10 billion in 2024 and is expected to witness robust growth during the forecast period, registering a compound annual growth rate (CAGR) of 7.45% through 2030.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 5.10 Billion
Market Size 2030	USD 7.87 Billion
CAGR 2025-2030	7.45%
Fastest Growing Segment	Humira
Largest Market	North America

Ankylosing spondylitis is a chronic, inflammatory autoimmune disorder that predominantly affects the spine, leading to persistent pain, stiffness, and reduced mobility. Classified within the group of spondyloarthritis disorders, AS can also involve peripheral joints and various organs. The market for AS therapeutics has experienced notable progress in recent years, fueled by advancements in clinical research, the introduction of novel treatment modalities, and increased global awareness of the disease.

AS is marked by inflammation of the sacroiliac joints, connecting the sacrum at the base of the spine to the pelvis. Over time, this inflammation can result in the fusion of spinal vertebrae, severely limiting spinal flexibility and altering posture. Typically manifesting in early adulthood, common symptoms include lower back pain and morning stiffness. Timely diagnosis and effective disease management are essential to enhancing patients' quality of life.

Ankylosing spondylitis is a global health concern, affecting millions of individuals worldwide. Prevalence rates vary by region and population, with genetic factors-particularly the HLA-B27 gene-playing a major role in disease development. The AS therapeutics market has expanded considerably in recent years due to earlier diagnoses, increased treatment accessibility, and the availability of advanced therapeutics.

Key Market Drivers

Rising Prevalence of Ankylosing Spondylitis

The increasing global incidence of ankylosing spondylitis is a primary driver of market growth. Although AS affects a relatively small proportion of the population-ranging from 0.1% to 1.4%-its impact is significant, particularly among males and individuals in their most productive working years, often beginning in their mid-20s.

This growing patient base is intensifying the demand for effective, long-term therapeutic solutions, creating ample opportunities for pharmaceutical manufacturers and healthcare providers. Traditionally underdiagnosed due to its insidious onset and nonspecific symptoms, AS is now being identified earlier thanks to heightened awareness and advancements in diagnostic imaging technologies.

The ability to diagnose AS in its early stages enables earlier intervention, which enhances long-term treatment adherence and drives sustained demand for therapeutic products.

Key Market Challenges

Limited Awareness and Delayed Diagnosis

One of the core challenges faced by the AS therapeutics market is the limited awareness among both healthcare professionals and the general public. Misdiagnosis or late diagnosis remains a common issue, often resulting in delayed treatment and worsened patient outcomes. Addressing this gap through education and awareness campaigns is vital to improving early detection and disease management.

Key Market Trends

Technological Advancements in Diagnosis and Treatment

Emerging technologies have significantly improved the diagnostic accuracy and management of ankylosing spondylitis. Imaging techniques such as magnetic resonance imaging (MRI) and computed tomography (CT) are now routinely employed to detect early signs of inflammation and structural damage in the spine and sacroiliac joints. These high-resolution tools facilitate early diagnosis, which is crucial for initiating timely treatment.

Additionally, the integration of artificial intelligence (AI) and machine learning in image analysis has enhanced diagnostic precision. AI-driven tools are capable of identifying subtle pathological changes that might be overlooked by human evaluators, further supporting early and accurate diagnosis.

On the treatment front, advancements in biotechnology have led to the development of biological therapies-targeted drugs that address the specific immune mechanisms driving AS-related inflammation. TNF inhibitors have significantly improved patient outcomes by alleviating pain, stiffness, and inflammation. Furthermore, the emergence of biosimilars-cost-effective alternatives to biologic drugs-has broadened patient access to these life-changing treatments, especially in cost-sensitive markets.

Key Market Players

AbbVie, Inc.
Amgen, Inc.
Pfizer, Inc.
Novartis AG
Eli Lilly and Company
UCB, Inc.
Johnson & Johnson Services, Inc.
Merck & Co., Inc

Report Scope:

In this report, the Global Ankylosing Spondylitis Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Ankylosing Spondylitis Therapeutics Market, By Drug:

Cosentyx
Humira
Simponi
Remicade
Enbrel
Cimzia

Ankylosing Spondylitis Therapeutics Market, By End Use:

Hospitals
Clinics
Others

Ankylosing Spondylitis Therapeutics Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Ankylosing Spondylitis Therapeutics Market.

Available Customizations:

Global Ankylosing Spondylitis Therapeutics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Ankylosing Spondylitis Therapeutics Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Drug (Cosentyx, Humira, Simponi, Remicade, Enbrel, Cimzia)
- 5.2.2. By End Use (Hospitals, Clinics, Others)
- 5.2.3. By Region
- 5.2.4. By Company (2024)
5.3. Market Map

6. North America Ankylosing Spondylitis Therapeutics Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Drug
- 6.2.2. By End Use
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Ankylosing Spondylitis Therapeutics Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Drug
    - 6.3.1.2.2. By End Use
- 6.3.2. Canada Ankylosing Spondylitis Therapeutics Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Drug
    - 6.3.2.2.2. By End Use
- 6.3.3. Mexico Ankylosing Spondylitis Therapeutics Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Drug
    - 6.3.3.2.2. By End Use

7. Europe Ankylosing Spondylitis Therapeutics Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Drug
- 7.2.2. By End Use
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Ankylosing Spondylitis Therapeutics Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Drug
    - 7.3.1.2.2. By End Use
- 7.3.2. United Kingdom Ankylosing Spondylitis Therapeutics Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Drug
    - 7.3.2.2.2. By End Use
- 7.3.3. Italy Ankylosing Spondylitis Therapeutics Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Drug
    - 7.3.3.2.2. By End Use
- 7.3.4. France Ankylosing Spondylitis Therapeutics Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Drug
    - 7.3.4.2.2. By End Use
- 7.3.5. Spain Ankylosing Spondylitis Therapeutics Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Drug
    - 7.3.5.2.2. By End Use

8. Asia-Pacific Ankylosing Spondylitis Therapeutics Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Drug
- 8.2.2. By End Use
- 8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Ankylosing Spondylitis Therapeutics Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Drug
    - 8.3.1.2.2. By End Use
- 8.3.2. India Ankylosing Spondylitis Therapeutics Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Drug
    - 8.3.2.2.2. By End Use
- 8.3.3. Japan Ankylosing Spondylitis Therapeutics Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Drug
    - 8.3.3.2.2. By End Use
- 8.3.4. South Korea Ankylosing Spondylitis Therapeutics Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Drug
    - 8.3.4.2.2. By End Use
- 8.3.5. Australia Ankylosing Spondylitis Therapeutics Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Drug
    - 8.3.5.2.2. By End Use

9. South America Ankylosing Spondylitis Therapeutics Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Drug
- 9.2.2. By End Use
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Ankylosing Spondylitis Therapeutics Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Drug
    - 9.3.1.2.2. By End Use
- 9.3.2. Argentina Ankylosing Spondylitis Therapeutics Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Drug
    - 9.3.2.2.2. By End Use
- 9.3.3. Colombia Ankylosing Spondylitis Therapeutics Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Drug
    - 9.3.3.2.2. By End Use

10. Middle East and Africa Ankylosing Spondylitis Therapeutics Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Drug
- 10.2.2. By End Use
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Ankylosing Spondylitis Therapeutics Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Drug
    - 10.3.1.2.2. By End Use
- 10.3.2. Saudi Arabia Ankylosing Spondylitis Therapeutics Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Drug
    - 10.3.2.2.2. By End Use
- 10.3.3. UAE Ankylosing Spondylitis Therapeutics Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Drug
    - 10.3.3.2.2. By End Use

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions

13. Global Ankylosing Spondylitis Therapeutics Market: SWOT Analysis

14. Competitive Landscape

14.1. AbbVie, Inc.
- 14.1.1. Business Overview
- 14.1.2. Product & Service Offerings
- 14.1.3. Recent Developments
- 14.1.4. Financials (If Listed)
- 14.1.5. Key Personnel
- 14.1.6. SWOT Analysis
14.2. Amgen, Inc.
14.3. Pfizer, Inc.
14.4. Novartis AG
14.5. Eli Lilly and Company
14.6. UCB, Inc.
14.7. Johnson & Johnson Services, Inc.
14.8. Merck & Co., Inc